Literature DB >> 7477226

Extreme risk--the new corporate proposition for physicians.

S Woolhandler, D U Himmelstein.   

Abstract

Mesh:

Year:  1995        PMID: 7477226     DOI: 10.1056/NEJM199512213332510

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

1.  Beyond financial incentives: organizational ethics and organizational integrity.

Authors:  J Goodstein; R L Potter
Journal:  HEC Forum       Date:  1999-12

2.  You can't leap a chasm in two jumps: The Institute of Medicine health care quality report.

Authors:  G D Schiff; Q D Young
Journal:  Public Health Rep       Date:  2001 Sep-Oct       Impact factor: 2.792

3.  Global amnesia: embracing fee-for-non-service--again.

Authors:  David U Himmelstein; Steffie Woolhandler
Journal:  J Gen Intern Med       Date:  2014-05       Impact factor: 5.128

Review 4.  Funding Canada's health care system: a tax-based alternative to privatization.

Authors:  M Gordon; J Mintz; D Chen
Journal:  CMAJ       Date:  1998-09-08       Impact factor: 8.262

5.  Universal coverage: the best use of funds or the tragedy of the commons?

Authors:  M Gordon
Journal:  CMAJ       Date:  1996-09-15       Impact factor: 8.262

6.  The silence of the doctors: fifty years after Nuremberg.

Authors:  D U Himmelstein; S Woolhandler
Journal:  J Gen Intern Med       Date:  1998-06       Impact factor: 5.128

7.  The alluring myth of private medicine.

Authors:  M Gordon; P B Berger
Journal:  CMAJ       Date:  1996-08-15       Impact factor: 8.262

8.  Contemporary American medicine: a view from the trenches.

Authors:  M J DiNubile; N H DiNubile
Journal:  J Gen Intern Med       Date:  1996-03       Impact factor: 5.128

9.  Caring for America's poor.

Authors:  M Gordon
Journal:  Can Fam Physician       Date:  1998-04       Impact factor: 3.275

10.  Annotation: patients on the auction block.

Authors:  S Woolhandler; D U Himmelstein
Journal:  Am J Public Health       Date:  1996-12       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.